

## The Lancet—London

32 Jamestown Road,  
London NW1 7BY,  
UK  
T +44 (0)20 7424 4910  
F +44 (0)20 7424 4911

## The Lancet—New York

360 Park Avenue South,  
New York, NY 10010–1710,  
USA  
T +1 212 633 3810  
F +1 212 633 3853

## The Lancet—Beijing

Unit 1–6, 7F, Tower W1,  
Oriental Plaza, Beijing 100738  
China  
T + 86 10 85208872  
F + 86 10 85189297

editorial@lancet.com

## Editor

Richard Horton

## Deputy Editor

Astrid James

## Senior Executive Editors

Pam Das  
Sabine Kleinert  
William Summerskill

## Executive Editors

Justine Davies  
Ros Osmond  
Joanna Palmer  
Pia Pini  
Stuart Spencer  
Richard Turner

## Managing Editor

Stephanie Clark

## Web Editors

Richard Lane  
Erika Niesner

## Assistant Web Editor

Nicolai Humphreys

## Senior Editors

Niall Boyce  
Jane Godtsland  
Seema Kang  
Selina Lo  
Zoë Mullan  
Udani Samarasekera

## Asia Editor

Helena Hui Wang (Beijing)

## North American Senior Editor

Maja Zecevic (New York)

## Conference Editors

Laura Hart  
Elvira Manjaji

## Deputy Managing Editor

Hannah Cumber

## Senior Assistant Editors

Laura Benham  
Sean Cleghorn  
Tim Dehnel  
Katrina Phillips  
Onisillos Sekkides  
Farhat Yaqub

## Assistant Editors

Olaya Astudillo  
Abi Cantor  
Mario Christodoulou  
Dara Mohammadi  
Zena Nyakoojo  
Frances Whinder

## Media Relations Manager

Tony Kirby

## Editorial Assistants



Holly Baker  
Neil Bennet  
Katherine Rolfe  
Ambreen Tariq

THE LANCET® is a registered trademark of Elsevier Properties SA, used under licence.

## Editorial

- 199 HIV/AIDS and the road to Rome  
200 Warning: a hard habit to break  
200 Cardiovascular disease in women—often silent and fatal

## Comment

- 201 Rilpivirine: a step forward in tailored HIV treatment  
*R Schrijvers and others*  
203 The concurrency debate: time to put it to rest  
*NS Padian, S Manian*  
204 Test and treat in HIV: success could depend on rapid detection  
 *T Cohen, E L Corbett*  
206 Antiretrovirals for HIV prevention: translating promise into praxis  
*K H Mayer*  
208 Treatment as prevention—a double hat-trick  
*J S G Montaner*  
209 Treatment 2.0: catalysing the next phase of scale-up  
 *G Hirschall, B Schwartländer*  
211 Let there be light: The Wakley Prize 2011  
*N Boyce and others*  
212 Offline: A seeker of silences  
*R Horton*

## World Report

- 213 Quest for an effective AIDS vaccine takes a new tack  
*J Maurice*  
215 Battles with donors cloud Malawi's HIV prevention plan  
*J Donnelly*




## Perspectives

- 217 Building the momentum to prevent HIV in MSM  
*T J Coates*  
218 Bertrand Audoin: promoting a global strategy for IAS  
*U Samarasekera*  
219 Kamiar and Arash Alaei: championing HIV/AIDS initiatives in Iran  
*P Shetty*  
220 Should health professionals play the global health security card?  
*S Elbe*


## Obituary

- 222 Peter John Liff  
*G Watts*


## Correspondence

- 223 Response to Correspondence on Great Ormond Street Hospital  
 *K Holt*  
223 Great Ormond Street Hospital and its management team  
 *T Blackstone and others*  
224 Radiology service at Great Ormond Street Hospital  
 *K Chong and others*  
224 HPTN 052 and the future of HIV treatment and prevention  
*W Cates; H Epstein, M Morris; A Seale and others*  
226 A strategic revolution in HIV and global health  
*R England*  
226 Body-mass index, abdominal adiposity, and cardiovascular risk  
*S Yusuf, S Anand; F B Gonçalves and others; D Wormser and others*  
228 Department of Error

## Articles

- 229 Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naïve adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial  
*C J Cohen and others*  
238 Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial  
*J-M Molina and others*  
247 Effect of concurrent sexual partnerships on rate of new HIV infections in a high-prevalence, rural South African population: a cohort study  
*F Tanser and others*  
256 The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study  
 *K A Powers and others*


## Review


- 269 HIV prevention transformed: the new prevention research agenda  
 *NS Padian and others*


## Viewpoint

- 279 Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women  
*S S Abdool Karim and others*  
282 Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach  
*E J Schouten and others*  
285 Can further placebo-controlled trials of antiretroviral drugs to prevent sexual transmission of HIV be justified?  
*L Kuhn and others*

## Case Report

- 288 Uncommon reaction to a common prescription  
 *K Khodakaram, N Barmano*

 Peer reviewed and fast-tracked to publication in 4 weeks

 Previously published online

 See [www.thelancet.com](http://www.thelancet.com) for WebExtra content

## International Advisory Board

Karen Antman (Boston)  
Valerie Beral (Oxford)  
Robert Beaglehole (Auckland)  
Anthony Costello (London)  
Robert Fletcher (Boston)  
Suzanne Fletcher (Boston)  
Karen Gelmon (Vancouver)  
David Grimes (Durham)  
Ana Langer (Mexico City)  
Judith Lumley (Melbourne)  
Elizabeth Molyneux (Blantyre)  
Christopher Murray (Seattle)

Alwyn Mwinga (Lusaka)  
Marie-Louise Newell (Somkhele)  
Magne Nylenna (Oslo)  
Peter Piot (London)  
Stuart Pocock (London)  
Giuseppe Remuzzi (Bergamo)  
Caroline Savage (Birmingham)  
Ken Schulz (Chapel Hill)  
Frank Shann (Melbourne)  
Jan Vandenbroucke (Leiden)  
Cesar Victora (Pelotas)  
Nick White (Bangkok)

## Information for Authors

See [www.thelancet.com](http://www.thelancet.com) for guidelines for authors.

## Ombudsman

Charles Warlow  
(c/o [The Lancet](http://The Lancet) or [ombudsman@lancet.com](mailto:ombudsman@lancet.com))